Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 10/20 | 0.52 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656714 | 0.90 | ADAM17 (0.45) | ADAM17MMP13MMP9MMP1ALDH1A1 | |
| SCHEMBL6662479 | 0.89 | ADAM17 (0.44) | ADAM17MMP13MMP9ALDH1A1KDM4E | |
| SCHEMBL6655286 | 0.89 | ADAM17 (0.51) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL6656661 | 0.84 | ADAM17 (0.44) | ADAM17MMP13MMP9MMP1KMT2A | |
| SCHEMBL6658036 | 0.82 | PSMB5 (0.39) | ADAM17MMP13MMP9MMP1KDM4E | |
| SCHEMBL6654871 | 0.81 | ADAM17 (0.43) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL6660841 | 0.81 | MAOB (0.43) | ADAM17MMP13MMP9KMT2AGAA | |
| SCHEMBL6662581 | 0.80 | HTT (0.51) | ALDH1A1CYP3A4CYP2C19HTTKMT2A | |
| SCHEMBL6656469 | 0.79 | ADAM17 (0.56) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL30692446 | 0.75 | KDM4E (0.54) | ADAM17MMP13MMP9MMP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147080-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | MMP12, MMP17, MMP14 | ADAM17 7/4885MMP13 12/4885MMP9 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.